Top 50 Biotechnology VC Funds & Investors in Austria (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
XISTA Science Ventures
VC Fund
|
13 | Austria, Germany, France | Seed, Pre-Seed, Series A | Biotechnology, Medical, Software | $511k–$20M |
|
xista science ventures
VC Fund
|
9 | Austria, Slovenia | Seed, Pre-Seed, Series A | Biotechnology, Medical, Software | $511k–$20M |
|
tecnet equity
VC Fund
|
7 | Austria | Seed, Series A | Software, SaaS, Biotechnology | $400k–$6M |
|
austria Wirtschaftsservice (aws)
VC Fund
|
5 | Austria, Belgium | Seed, Grant, Pre-Seed | Software, Information Technology, Artificial Intelligence | $62k–$2.7M |
|
SOSV
VC Fund
|
5 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
MIG Capital
VC Fund
|
4 | Germany, France, Austria | Series A, Series B | Biotechnology, Health Care, Therapeutics | $1.6M–$54M |
|
PUSH VC
VC Fund
|
3 | Austria, Germany, United States | Seed, Series A | Software, Apps, Health Care | $650k–$31M |
|
aws Gründungsfonds
VC Fund
|
3 | Austria, Germany, United States | Seed, Series A | Software, SaaS, Information Technology | $1.1M–$12M |
|
APEX Ventures
VC Fund
|
2 | Germany, United Kingdom, Austria | Seed, Series A, Pre-Seed | Artificial Intelligence, Software, Health Care | $511k–$22M |
|
BackBone Ventures
VC Fund
|
2 | Switzerland, Germany, Israel | Pre-Seed, Seed, Series A | Artificial Intelligence, Information Technology, Software | $578k–$105M |
|
eQventure
VC Fund
|
2 | Austria, Switzerland | Seed, Series A | Software, Information Technology, Artificial Intelligence | $549k–$6.3M |
|
Ligand Pharmaceuticals
VC Fund
|
2 | United States, Austria, Denmark | Post-IPO Debt, Corporate Round, Post-IPO Equity | Biotechnology, Medical, Health Care | $3M–$90M |
|
Verge HealthTech Fund
VC Fund
|
2 | Estonia, Singapore, United Kingdom | Seed, Pre-Seed, Series A | Health Care, Medical Device, Medical | $500k–$4.7M |
|
VP Venture Partners
VC Fund
|
2 | Austria, Switzerland | Seed | Medical, Health Diagnostics, Internet | $3M–$6.9M |
|
Gamma Capital Partners
VC Fund
|
2 | Austria, United States, Germany | Series A, Seed | Software, Manufacturing, Information Technology | $406k–$8M |
|
The Austrian Research Promotion Agency (FFG)
VC Fund
|
2 | Austria, United States, Belgium | Grant, Seed, Pre-Seed | Software, Artificial Intelligence, Medical | $67k–$3.5M |
|
Übermorgen Ventures
VC Fund
|
2 | Germany, Switzerland, Finland | Seed, Pre-Seed, Series A | Software, Energy, Renewable Energy | $300k–$12M |
|
TSVC
VC Fund
|
2 | United States, China, Canada | Seed, Series A | Software, Artificial Intelligence, Health Care | $500k–$55M |
|
Longevitytech.fund
VC Fund
|
2 | United States, United Kingdom, The Netherlands | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Life Science | $100k–$10M |
|
Simon Capital
VC Fund
|
2 | Germany, Austria, The Netherlands | Series A, Seed, Series B | Software, Biotechnology, Food and Beverage | $1.7M–$57M |
|
SkyGene
VC Fund
|
2 | Austria | Venture - Series Unknown | Medical, Health Care, Biotechnology | |
|
KHAN Technology Transfer Fund
VC Fund
|
2 | Germany, Austria, Luxembourg | Seed, Series A, Venture - Series Unknown | Biotechnology, Medical, Biopharma | $259k–$10M |
|
FPS-Holding
VC Fund
|
2 | Austria | Seed | Biotechnology, Health Diagnostics | $420k–$429k |
|
red-stars.com
VC Fund
|
2 | Austria, Germany | Seed, Series A | Software, Biotechnology, Telecommunications | $1.6M–$4.4M |
|
Aescap Venture
VC Fund
|
2 | United Kingdom, Austria, Belgium | Series A, Series B | Biotechnology, Pharmaceutical, Chemical | $1.5M–$33M |
|
Nina Capital
VC Fund
|
2 | United States, United Kingdom, Germany | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $573k–$21M |
|
Lansdowne Partners
VC Fund
|
2 | United Kingdom, Austria, United States | Series A, Series B | Biotechnology, Finance, Genetics | $6.7M–$100M |
|
10x Founders
VC Fund
|
2 | Germany, United States, Switzerland | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Information Technology | $1.1M–$60M |
|
Arax Capital Partners
VC Fund
|
2 | Austria | Seed | Biotechnology, Health Care, Medical | |
|
bmp Ventures
VC Fund
|
2 | Germany, United States, Austria | Seed, Series A | Software, Information Technology, Manufacturing | $30k–$5.9M |
|
R42 Group
VC Fund
|
2 | United Kingdom, United States, Austria | Seed, Pre-Seed, Series A | Biotechnology, Health Care, Software | $439k–$40M |
|
Die Wirtschaftskammer
VC Fund
|
1 | Austria | Seed, Pre-Seed | Software, Music, mHealth | |
|
Wellcome Trust
VC Fund
|
1 | United States, United Kingdom, France | Grant, Series C | Biotechnology, Health Care, Medical | $1.6M–$127M |
|
Forbion Capital Partners
VC Fund
|
1 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $16M–$176M |
|
FCPG Affi
VC Fund
|
1 | Austria | Medical, Biotechnology, Pharmaceutical | ||
|
GLS Ventures
VC Fund
|
1 | Austria | Series B | Medical, Health Care, Biotechnology | |
|
Synthesis Capital
VC Fund
|
1 | United States, Israel, Austria | Seed, Series A, Series C | Biotechnology, Food and Beverage, Organic Food | $7.1M–$23M |
|
EIT Health
VC Fund
|
1 | United Kingdom, Spain, Ireland | Grant, Pre-Seed, Seed | Health Care, Medical Device, Medical | $22k–$1.6M |
|
ReGen Ventures
VC Fund
|
1 | United States, Germany, United Kingdom | Seed, Series A, Pre-Seed | Biotechnology, Agriculture, Farming | $2M–$20M |
|
Polaris Partners
VC Fund
|
1 | United States, Ireland, Singapore | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $4.5M–$107M |
|
4SC
VC Fund
|
1 | Austria | Seed | Health Care, Biotechnology | |
|
Andera Partners
VC Fund
|
1 | France, United States, Germany | Series B, Private Equity | Biotechnology, Health Care, Medical | $14M–$247M |
|
OrbiMed
VC Fund
|
1 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $10M–$151M |
|
Air Street Capital
VC Fund
|
1 | United States, United Kingdom, France | Seed, Series A, Series B | Artificial Intelligence, Software, Biotechnology | $2.6M–$300M |
|
42CAP
VC Fund
|
1 | Germany, France, Sweden | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, SaaS | $1.3M–$28M |
|
Venture Partners AG
VC Fund
|
1 | Austria, United States | Seed, Series B | Internet, Software, Biotechnology | |
|
Amino Collective
VC Fund
|
1 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Artificial Intelligence | $125k–$37M |
|
Possible Ventures
VC Fund
|
1 | Germany, Australia, United States | Seed, Pre-Seed, Series A | Software, Biotechnology, Information Technology | $549k–$47M |
|
EMBL Ventures
VC Fund
|
1 | Germany, Austria, Ireland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.9M–$70M |
|
FastVentures
VC Fund
|
1 | Hungary, South Korea, United States | Seed, Series A, Series B | Software, Biotechnology, Health Care | $424k–$31M |
| Access all 148 VC funds in Austria Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
We invest in deep tech startups and academic spin-offs with a strong innovation based on science, engineering and technology. We invest as lead investor in pre-seed and seed stages and have the ability to follow on in later rounds. We understand the needs of science and tech based startups and offer tailored support for entrepreneurs. We areembedded in the venture capital scene, yet understand the language of science and the world of research. Thanks to our diverse team, our expertise and experience in technology, entrepreneurship, finance, legal, IP, and strategic consulting will support your startup right from the start.
Show more...Investment focus
- Industry: Biotechnology, Medical, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Austria, Germany, France
Investor stats
- Total investments: 37
- Round size: Seed $1.8M–$6.9M; Pre-Seed $511k–$2.3M; Series A $5.2M–$20M
- Lead/follow: 59% lead, 41% follow
Portfolio highlights
- Ora Computing — Ora Computing is an AI infrastructure startup focused on compressing and optimizing large AI models, especially Large Language Models (LLMs), to make them cheaper and more efficient to deploy.
- G.ST Antivirals — G.ST Antivirals focuses on the development of antiviral drugs. G.ST Antivirals utilizes the viral dependency on the host cell metabolism and exploits this to design specific interventions counteracting viral nutrient supply.
- Epitome Therapeutics — Epitome Therapeutics is an early-stage biotechnology company developing CADENCE, a next-generation epigenome editing platform for precise, durable, and context-dependent control of gene expression without altering the underlying DNA sequence, with the aim of establishing a new therapeutic modality for diseases driven by dysregulated gene activity.
We invest in deep tech startups and academic spin-offs with a strong innovation based on science, engineering and technology. We invest as lead investor in pre-seed and seed stages and have the ability to follow on in later rounds. We understand the needs of science and tech based startups and offer tailored support for entrepreneurs. We areembedded in the venture capital scene, yet understand the language of science and the world of research. Thanks to our diverse team, our expertise and experience in technology, entrepreneurship, finance, legal, IP, and strategic consulting will support your startup right from the start.
Show more...Investment focus
- Industry: Biotechnology, Medical, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Austria, Slovenia
Investor stats
- Total investments: 22
- Round size: Seed $1.8M–$7.8M; Pre-Seed $511k–$1.5M; Series A $5.2M–$20M
- Lead/follow: 64% lead, 36% follow
Portfolio highlights
- subdron — subdron turns the seabed from a blind spot into a monitored domain.
- infrared.city — Redefine environmental simulations. Our bespoke AI models revolutionise performative design, slashing time, cost, and complexity. Access cutting-edge services effortlessly because innovation should be for everyone
- VALANX Biotech — VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development.
tecnet equity is an Austrian venture capital fund investing in innovative high-tech companies with potential for significant growth.
Show more...Investment focus
- Industry: Software, SaaS, Biotechnology
- Stage:Seed, Series A
- Geography: Austria
Investor stats
- Total investments: 65
- Round size: Seed $400k–$2.5M; Series A $583k–$6M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — last raise in 2009
Portfolio highlights
- Sipfront — Sipfront helps telecom operators to deliver better services by automating 24/7 active monitoring and by providing a test framework to simulate customer calls at scale
- VALANX Biotech — VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development.
- Greenwood-Power — Greenwood-Power is the leading innovator for non-conventional transformers. Let's talk about your individual requirements - CONTACT US TODAY!
The Austrian Economic Service mbH (aws) is the promotional bank of the Federal Government.The aws SME fund is the largest Austrian Fund for silent corporate investments, but also providers of equity. Founded in late 2009 by the Austrian Economic Service mbH (aws) - the Development Bank of the Federal - he has a term until 31/12/2025.The fund is currently endowed with EUR 80 million and participates in medium-sized companies and brings with it a fresh capital to develop new products or processes, for sales development to international expansion.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Grant, Pre-Seed
- Geography: Austria, Belgium
Investor stats
- Total investments: 67
- Round size: Seed $439k–$2.7M; Grant $62k–$2.3M; Pre-Seed $68k–$1.6M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- Repentium — Repentium serves industrial manufacturers seeking reproducible, cost-efficient 3D printing and engineering-grade plastic parts.
- Another Earth — Another Earth is building an AI-powered simulation and synthetic data platform for Earth Observation. As our planet changes, AI models need scalable, high-quality training data to keep pace. Another Earth provides synthetic data, scenario simulations and predictions required to accelerate AI development, and enable faster, smarterdecision-making—enabling smarter decisions for a more resilient world.
- Epitome Therapeutics — Epitome Therapeutics is an early-stage biotechnology company developing CADENCE, a next-generation epigenome editing platform for precise, durable, and context-dependent control of gene expression without altering the underlying DNA sequence, with the aim of establishing a new therapeutic modality for diseases driven by dysregulated gene activity.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
MIG Capital is one of the leading German VC Investors. We invest in European Deep Tech and Life Sciences from early to late stage (Seed, Series A, and beyond). We use investments to shape a better tomorrow, today. Our team currently manages 17 MIG public venture capital funds regulated by BaFin, the German financial markets authority. These fundsoperate with more than EUR 1.2 billion capital committed by >60,000 private investors across Germany and Austria.Today, our portfolio consists of 30 companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: Germany, France, Austria
Investor stats
- Total investments: 96
- Round size: Series A $2.2M–$40M; Series B $1.6M–$54M
- Lead/follow: 45% lead, 55% follow
- Last fund: May invest from a new fund soon — raised $70M in 2014
Portfolio highlights
- NcodiN — The High Performance Computing (HPC) and ArtificiaI Intelligence (AI) era requires unprecedented computing capabilities. With this in view, industry is heading towards zettascale supercomputers, based on >100k processing units. Chiplets-based disaggregated processors and memory-centric computing architectures are taking over and require an ever more intensive communication between dies. Thus, today interconnect bottleneck is the main
- GlassPoint Solar — GlassPoint provides solar steam generators to the oil and gas industry for applications such as Enhanced Oil Recovery. It replaces gas-fired steam generation with solar, GlassPoint can reduce EOR gas consumption by up to 80 percent. The company was founded in 2008 and headquartered in Fremont, California.
- Zadient Technologies — Zadient produces semiconductor manufacturing materials that are critical for the entire silicon carbide (SiC) value chain
| Investments that move industries
Show more...Investment focus
- Industry: Software, Apps, Health Care
- Stage:Seed, Series A
- Geography: Austria, Germany, United States
Investor stats
- Total investments: 44
- Round size: Seed $650k–$8.1M; Series A $5M–$31M
- Lead/follow: 18% lead, 82% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Gustav — Modern staffing teams use Gustav's VMS to source talent from trusted sub-vendors. Fast, secure, and compliant!
- Voltrac — Voltrac is a robotics company that develops an autonomous, fully electric tractor platform called THOR, designed to operate in demanding environments for both agricultural and logistics use. THOR employs per-wheel electric motors instead of a conventional drivetrain, reducing mechanical complexity and maintenance requirements. It runs on swappable200 kWh battery packs, enabling long-duration operations and continuous work cycles. The platform supports a standard three-point hitch (Category II) and can be configured with a flatbed, making it versatile for fieldwork or transport tasks. Voltrac’s autonomy system combines reinforcement learning with real-time sensor data to adapt driving behavior and implements to changing terrain and crop conditions. Beyond farming, THOR is also intended for frontline logistics missions, with modular designs that can support cargo transport and resilience in challenging settings.
- enspired — Revolutionize battery storage with AI-powered BESS optimization. Our energy trading platform ensures smart, real-time market access. Contact us today!
aws Gründerfonds is Austria's 70m venture capital fund. We invest as co-investor in Austrian high-growth start-ups in their later seed and (pre-)series-A stages.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Seed, Series A
- Geography: Austria, Germany, United States
Investor stats
- Total investments: 90
- Round size: Seed $1.3M–$5.2M; Series A $1.1M–$12M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- refinq — Our platform helps companies transform climate and biodiversity risks into opportunities to reduce costs, future-proof operations, and stay competitive.
- NodeVenture — The NodeVenture Secure Wallet System is a globally unique solution for the safekeeping of crypto assets. With our patented Air Wall technology, we store crypto assets offline around the clock to protect them from hacker attacks. Nevertheless, users can access their assets 24/7 and fully automated via our NodeVenture web application. No humanintervention is required to switch from the online to the offline area or vice versa. Through the HD-Wallet process (BIP44), the sensitive private keys are only generated when they are needed for transactions. They do not remain in the temporary or permanent data storage for a second (derivation of the private keys "on-the-fly"). This also offers significant advantages for recovery. We offer the NodeVenture Secure Wallet System to institutional financial market participants, depending on customer needs. TMIA is a qualified and ISO27001 certified custodian regulated in Austria.
- vitrealab — Enlighten. Your perspective. Light Engines for AR glasses.
APEX Ventures is a deep-tech and medical-focused venture capital firm.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, United Kingdom, Austria
Investor stats
- Total investments: 53
- Round size: Seed $1.3M–$8M; Pre-Seed $511k–$9.1M; Series A $2.2M–$22M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- GEMESYS — Gemesys creates a chip that functions similarly to the human brain in order to overcome processing constraints and empower AI with the hardware it needs to complete its destiny
- HyperHeat — HyperHeat is building a cutting-edge, all-electric heating solution designed to reach temperatures of up to 2,000°C. Using renewable electricity HyperHeat is providing an efficient alternative to fossil fuel combustion. With an efficiency rate of up to 98%, HyperHeat is ideal for retrofitting industrial processes, enabling significant CO2reductions across industries like steel, cement, and chemicals. The scalable technology offers a cost-efficient approach to decarbonizing thermal processes, with a potential to reduce global CO2 emissions by over 4.5 gigatons annually.
- TriLite Technologies — The world's smallest projection displays from TriLite take laser beam scanning technology to the next level, for augmented vision as light as the eyewear of today.
BackBone Ventures' focus are early-stage investments, primarly in the area of innovative ICT, FoodTech and disruptive technologies in DACH & Israel. Committed to achieve a positive impact for the next generation by empowering access to proficient ventures investments.
Show more...Investment focus
- Industry: Artificial Intelligence, Information Technology, Software
- Stage:Pre-Seed, Seed, Series A
- Geography: Switzerland, Germany, Israel
Investor stats
- Total investments: 71
- Round size: Seed $966k–$5M; Pre-Seed $578k–$2.1M; Series A $5M–$105M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Qala — Qala delivers real-time data classification, discovery, and policy enforcement. Auto-classify sensitive data, map full lifecycles, and label at source.
- eternal.ag — eternal.ag develops robotics and AI solutions for greenhouse farming. It builds autonomous robots, like its flagship Harvester for tomatoes, to address labor shortages and enable year-round fresh produce production.
- Boostbar — Boostbar AG developed a smart food vending machines sold to other businesses.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Entrepreneurs for Entrepreneurs
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A
- Geography: Austria, Switzerland
Investor stats
- Total investments: 58
- Round size: Seed $549k–$1.2M; Series A $768k–$6.3M
- Lead/follow: 78% lead, 22% follow
Portfolio highlights
- Diamens — Diamens is a company focused on femtech that develops a non-invasive menstrual blood-based molecular diagnostic to detect women-specific diseases like endometriosis.
- Respory — Respory provides real-time people-tracking using proprietary radar sensors, all without capturing personal data. Our scalable sensor network, powered by AI-driven algorithms, delivers precise customer journey insights, critical for in-store performance in retail.
- 2nd Cycle — 2nd Cycle creating a cost-effective, fully automated, and scalable solution for modules for a second life cycle.
A genetic medicines company developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Post-IPO Debt, Corporate Round, Post-IPO Equity
- Geography: United States, Austria, Denmark
Investor stats
- Total investments: 17
- Round size: Post-IPO Debt $15M–$75M; Corporate Round $3M–$10M; Post-IPO Equity $15M–$90M
- Lead/follow: 59% lead, 41% follow
Portfolio highlights
- Zerion Pharma — Zerion Pharma is a pharmaceutical company that aims to transform the pharmaceutical landscape with a new formulation technology. The company is focused on improving existing drugs by building an internal pipeline to solve the most challenging drug solubility problems that pharmaceutical companies face. Zerion Pharma was founded in 2019 and isbased in Birkerød, Denmark.
- Orchestra BioMed — We are a biomedical innovation company focused on developing transformative therapeutic products for large unmet clinical needs in procedure-based medicine
- Castle Creek Biosciences — Dedicated to making life better for people suffering from rare diseases with few or no treatment options
We make early investments in global healthcare technology companies that address prevention, disease management and health system efficiency that are relevant to emerging AsiaWe believe that innovation can happen anywhere, from the streets of Dhaka to the labs of Oxford, however without the right support network, these solutions might notscale, or find the best world-changing application. This is where we can help.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Seed, Pre-Seed, Series A
- Geography: Estonia, Singapore, United Kingdom
Investor stats
- Total investments: 28
- Round size: Seed $500k–$4.7M; Pre-Seed $500k–$1M
- Lead/follow: 54% lead, 46% follow
- Last fund: May invest from a new fund soon — raised $17k in 2021
Portfolio highlights
- Zoundream — The Future of Infant Care
- Understanding Zoe — Understanding Zoe is a neuroaffirming application that turns every report and observation into an actionable step for a better connect.
- Neuraworx Medical Technology — Neuraworx Medical Technology is a neurotechnology company developing first-in-class bioelectronic solutions for brain health.
VP Venture Partners is a venture capital firm invests in healthcare companies.
Show more...Investment focus
- Industry: Medical, Health Diagnostics, Internet
- Stage:Seed
- Geography: Austria, Switzerland
Investor stats
- Total investments: 6
- Round size: Seed $3M–$6.9M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Diamens — Diamens is a company focused on femtech that develops a non-invasive menstrual blood-based molecular diagnostic to detect women-specific diseases like endometriosis.
- Moonlight AI — Moonlight AI empowers pathologists and hematologists to make therapeutic decisions backed by genomic insight. Moonlight AI was founded in 2022 and is headquartered in Jura, Switzerland.
- CollimateHealth — CollimateHealth is creating a clinically scalable microbeam radiation technology that will revolutionize the treatment of cancer.
gcp gamma capital partners is an independent Venture Capital investment firm, focused on financing dynamic technology companies in Austria, Germany, Switzerland and CEE countries.They seek to achieve superior returns by finding assets with substantial potential in their regional and sectoral focus areas, before they appear on the radar screenof mainstream players in terms of stage and/or initial investment size.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Series A, Seed
- Geography: Austria, United States, Germany
Investor stats
- Total investments: 29
- Round size: Seed $406k–$636k; Series A $1.3M–$8M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Icomasoft — Icomasoft ag is a Swiss pioneer of agent-less software solutions providing unprecedented transparency across your virtual and physical IT infrastructure in heterogeneous datacenters.IcomasoftÂ:registered: software solutions collect essential information for mission-critical and business-critical decisions and provide simplified, automated tasksthat support administrators, IT managers and Executives to easily and confidently analyze, plan and optimize their IT capacity. icomasoftÂ:registered: software solutions are vital for your datacenter clarity.
- Henn GmbH & Co KG — Henn GmbH & Co KG develops and commercializes rapid connecting systems for hoses in automotive engine blocks.
- CNSystems Medizintechnik — CNSystems Medizintechnik sells, manufactures, and develops equipment for non-invasive, continuous monitoring of blood pressure and other essential vital parameters. The company was founded in May 1998 as a spin-off from the Medical University and University of Technology Graz, Austria.
The Austrian Research Promotion Agency (FFG) is the national funding agency for industrial research and development in Austria. As a "one-stop shop" offering a diversified and targeted programme portfolio, the FFG gives Austrian businesses and research facilities quick and uncomplicated access to research funding.The FFG was foundedon 1 September 2004 (pursuant to the FFG Act on establishing a research promotion agency, Federal Law Gazette I No. 73/2004). The FFG is wholly owned by the Republic of Austria, represented by the Federal Ministry for Transport, Innovation and Technology (bmvit) and the Federal Ministry of Science, Research and Economy (BMWFW). As a provider of funding services, however, the FFG also works for other national and international institutions.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Medical
- Stage:Grant, Seed, Pre-Seed
- Geography: Austria, United States, Belgium
Investor stats
- Total investments: 70
- Round size: Seed $300k–$2.2M; Grant $67k–$3.5M; Pre-Seed $480k–$1.9M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- OPTIMUSE — Optimuse provides an AI-based solution that supports the pre-design phase of building renovation. The platform converts building data into a digital twin to create accurate models for planning. It integrates data such as room types, thermal properties, and HVAC systems. The system runs energy simulations to calculate heating, cooling, lighting, andequipment needs. It helps design technical systems by defining the quantity, sizing, and configuration of components. The platform develops renovation plans by modeling financial, energy, and emissions outcomes. It also offers tools for cost calculation, performance monitoring, and collaboration across project teams.
- sequestra — Sequestra is developing a technology platform that allows for permanent binding of CO₂ in industrial residues such as steel slag, incineration ash, and demolition waste while making the carbonated materials usable for construction applications.
- Another Earth — Another Earth is building an AI-powered simulation and synthetic data platform for Earth Observation. As our planet changes, AI models need scalable, high-quality training data to keep pace. Another Earth provides synthetic data, scenario simulations and predictions required to accelerate AI development, and enable faster, smarterdecision-making—enabling smarter decisions for a more resilient world.
We are an early stage VC for climate tech startups.
Show more...Investment focus
- Industry: Software, Energy, Renewable Energy
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Switzerland, Finland
Investor stats
- Total investments: 51
- Round size: Seed $2.2M–$6.2M; Pre-Seed $300k–$4.1M; Series A $2.7M–$12M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Ecair — Ecair provides software for indoor air quality and energy management. The platform aggregates data from connected sensors to track pollutants, CO2, humidity, temperature, and particulate matter in real time. Dashboards, alerts, and APIs support building operations, facility managers, and ESG teams. Algorithms estimate exposure, flag ventilationissues, and suggest HVAC adjustments to balance comfort, health, and energy use. Reporting tools support certifications and compliance, and data exports integrate with BMS, CMMS, and data warehouses. Services include device provisioning, calibration management, and analytics consulting for multi-site portfolios.
- Verna — Verna is a business using geospatial data science to address the climate and nature crises.We help landowners, investors, and policymakers to use land in ways that draw down carbon, enhance biodiversity and generate sustainable returns – e.g. through woodland creation, habitat creation and enhancement, and regenerative agriculture.Verna wasestablished in Borehamwood, Hertford.
- Exnaton — Exnaton offers a flexible SaaS platform for the decarbonized, decentralized and digital energy future. We move ahead with energy communities. Exnaton offers software for energy communities and dynamic energy tariffs. With our SaaS solution, utilities can easily build a digital customer channel, offer new renewable energy products, and reduce manual effort for managing distributed resources. We enable energy communities according to REDII, models for shared investments in photovoltaic, batteries and more, collective self-consumption billing, self-consumption communities and participation models for tomorrow's energy market.
Founded in 2010, TSVC (formerly TEEC Angel Fund) is proud to be a leading early-stage venture capital fund in Silicon Valley.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A
- Geography: United States, China, Canada
Investor stats
- Total investments: 263
- Round size: Seed $500k–$7M; Series A $2.7M–$55M
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Preveta — An intelligent care navigation platform designed for specialty care
- BloomTech — BloomTech provides online technical coding courses including data science, full-stack web and backend development, and free coding courses.
- Path — We help you acquire the perfect domain for your site. Affordable payment options. Quick and responsive customer support available.
Investing globally in technologies extending healthy lifespans
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 49
- Round size: Seed $1.7M–$10M; Pre-Seed $100k–$3.2M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Whytics — DAGI: higher-level causal models from spatiotemporal coarse‑graining Whytics builds tools to reveal and validate macro‑causal structure—the stable, higher-level variables that appear when many parts of a system interact across space and time.
- Klothea Bio — Klothea Bio is a protein well known for its powerful anti-aging capabilities, such as tumor suppression, neuroprotection, and antioxidative actions. As people age, their klotho levels drop to harmful levels. The metabolic disease syndrome will be the focus of the first investigations, while later studies will try to extend therapeutic applicationsto cancer, Alzheimer's disease, obesity, and other age-related diseases.
- Yuva Biosciences — Using cutting edge mitochondrial science to develop cosmeceuticals and pharmaceuticals.
Simon Capital is an early-stage VC fund with €105M capital ready to invest in innovations that will improve our everyday lives, following the mission of investing “for the next generation”.
Show more...Investment focus
- Industry: Software, Biotechnology, Food and Beverage
- Stage:Series A, Seed, Series B
- Geography: Germany, Austria, The Netherlands
Investor stats
- Total investments: 21
- Round size: Seed $1.8M–$9.3M; Series A $1.7M–$14M; Series B $32M–$57M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely still investing — raised $123M in 2022
Portfolio highlights
- VisioLab — Instantly scan products for self-checkout, using the iPad camera - no barcodes needed. Designed for speed, simplicity and human centricity.
- eternal.ag — eternal.ag develops robotics and AI solutions for greenhouse farming. It builds autonomous robots, like its flagship Harvester for tomatoes, to address labor shortages and enable year-round fresh produce production.
- Pacifico Biolabs — Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of sustainable and food alternatives.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!SkyGene is a venture capital firm. The firm intends to invest in biotech firms.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Venture - Series Unknown
- Geography: Austria
Investor stats
- Total investments: 2
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- VALANX Biotech — VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development.
KHAN Technology Transfer Fund operates as an investment firm.
Show more...Investment focus
- Industry: Biotechnology, Medical, Biopharma
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Germany, Austria, Luxembourg
Investor stats
- Total investments: 14
- Round size: Seed $259k–$10M; Series A $5.5M–$10M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Casinvent Pharma — Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies.
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
- KyDo Therapeutics — KyDo Therapeutics is a biotechnology company that develops novel covalent-allosteric small molecule inhibitors.
SPV
Show more...Investment focus
- Industry: Biotechnology, Health Diagnostics
- Stage:Seed
- Geography: Austria
Investor stats
- Total investments: 2
- Round size: Seed $420k–$429k
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Sola Diagnostics — Product: Sola Diagnostics’ WID®-easy test is a non-invasive epigenetic solution for detecting endometrial cancer in women with abnormal uterine bleeding. By analyzing DNA methylation markers from a simple vaginal swab, it offers high accuracy, reducing false positives and unnecessary surgeries. Target Audience: Designed for gynecologists andhealthcare providers, WID®-easy streamlines diagnostics, cutting costs and false alarms. Women benefit from a painless, accessible test that ensures earlier and more precise detection. Technology: Powered by advanced DNA methylation research, WID®-easy identifies cancer-specific epigenetic markers. With PCR-based analysis and robust clinical validation, it delivers fast, reliable results that integrate seamlessly into medical workflows. Market Positioning: WID®-easy fills a critical gap as a first-line diagnostic for abnormal uterine bleeding. Its clinical validation, accuracy, and cost-efficiency set it apart from invasive procedures. Its ease of use and scalability position it for widespread adoption. Milestones: Sola Diagnostics launched in Austria and Switzerland in 2024 and expanded to Great Britain in 2025. UKCA Marking was registered in December 2024. So far, private equity investments totaling €2.4M have supported Sola's mission to revolutionize women’s health diagnostics.
We back B2B software and life-sciences companies with limitless scalability.
Show more...Investment focus
- Industry: Software, Biotechnology, Telecommunications
- Stage:Seed, Series A
- Geography: Austria, Germany
Investor stats
- Total investments: 8
- Round size: Seed $1.6M–$4.4M
- Lead/follow: 75% lead, 25% follow
Portfolio highlights
- Txture — End-To-End Cloud Transformation Platform
- HeartBeat.bio — HeartBeat.bio is a privately funded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathies.
- MAVOCO — We create a carrier-grade software for IoT champions, trusted by tier-1 Mobile network operators.
Aescap Venture is an Amsterdam-based investment company that pursues investments in biotech companies in Europe and the U.S.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Chemical
- Stage:Series A, Series B
- Geography: United Kingdom, Austria, Belgium
Investor stats
- Total investments: 18
- Round size: Series A $1.5M–$20M; Series B $5.2M–$33M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Biocartis — Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. We provide next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus on oncology.
- Vivendy Therapeutics — Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly
- Affectis Pharmaceuticals — Affectis is a pharmaceuticals company developing novel drugs for the treatment of neurodegenerative and neuroinflammatory diseases.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 89
- Round size: Seed $2M–$6.3M; Pre-Seed $573k–$2.4M; Series A $5M–$21M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Navidence — Navidence provides a transformative Real World Evidence (RWE) Design platform that enables organizations to efficiently adapt to the ever-increasing ecosystem of Real World Data (RWD) sources. The company unlocks the power of Computable Operational Definitions (CODefs) for RWE Design and RWD Assessment. Navidence's RWE Sherpa platform offerstools to streamline the process of defining an RWE study's data, making it easier for researchers to conduct their studies in the age of data.
- Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
- Ladder Health — Ladder Health offers virtual pediatric therapy and support for early childhood developmental delays, including speech and physical therapy.
Fundamental Equity Investing, since 1998
Show more...Investment focus
- Industry: Biotechnology, Finance, Genetics
- Stage:Series A, Series B
- Geography: United Kingdom, Austria, United States
Investor stats
- Total investments: 43
- Round size: Series A $6.7M–$55M; Series B $8.5M–$100M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Nattergal — Nattergal is a company with a mission to deliver nature recovery at scale, to provide vital benefits for society and sustainable financial returns.
- G.ST Antivirals — G.ST Antivirals focuses on the development of antiviral drugs. G.ST Antivirals utilizes the viral dependency on the host cell metabolism and exploits this to design specific interventions counteracting viral nutrient supply.
- amnis — Check out your possibilities to transfer money abroad, collect international payments and exchange currencies all in one account. Make payments fast with amnis.
Cutting-edge venture capital firm supporting the early-stage entrepreneurs building global businesses.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, United States, Switzerland
Investor stats
- Total investments: 90
- Round size: Seed $2.5M–$10M; Pre-Seed $1.1M–$12M; Series A $6.9M–$60M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Logicc — Logicc provides business solutions for various industries. It specializes in software development, automation, and data-driven technologies.
- Qorelo — Qorelo is a tech company that provides agentic AI software designed to accelerate ERP transformations. Qorelo's software automates and structures deliverables across the SAP Activate methodology.
- Huzzle — Stop chasing jobs. Huzzle collects the best opportunities from student societies and companies and only shows you the relevant ones. Download Huzzle today!
ARAX Capital Partners is an Austrian bio-tech and high-tech early stage investor with an exclusive focus on Austrian ventures. Companies need to be young, innovative (if possible with patentable technology) and must have already secured pre-seed funding to qualify for an investment
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed
- Geography: Austria
Investor stats
- Total investments: 5
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- AFFiRiS — AFFiRiS AG, a Vienna, Austria-based developer of tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, hypertension and several other conditions.
- Greenpass — Greenpass is a ClimateTech company providing the official greenpass for climate proof real estate. Build resilience and manage climate-proof assets and portfolios in line with ESG regulations while maximizing return on invest and value with ease.
- Calyxha Biotechnologies GmbH — A new perspective on inflammation
bmp Ventures is an innovative Venture Capital Company from Berlin. Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Seed, Series A
- Geography: Germany, United States, Austria
Investor stats
- Total investments: 120
- Round size: Seed $165k–$3.4M; Series A $30k–$5.9M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Sedivention — Fight obesity within 20 minutes - fast, effective, long-term. A new weight-loss therapy for the treatment of obesity. Just a view minutes will change your life.
- Solar Materials — SOLAR MATERIALS developed a recycling technology for solar modules, which recovers all raw materials for a circular solar industry.
- Litherm Technologies — Litherm Technologies GmbH is a German deep‑tech startup focused on decarbonizing lime and cement production using fully electric kiln technology.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!R42 Group is a venture fund and an institute which invents, invests and informs covering AI, deep science, 5G mobile, biotech and fintech.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Austria
Investor stats
- Total investments: 34
- Round size: Seed $654k–$8M; Pre-Seed $439k–$2M; Series A $4.2M–$40M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
- Stamp Free — stampfree.ai Digital Shipping Solutions enables customers to send parcels and returns with just a phone conveniently and securely.
- Cordance Medical — Improving outcomes for patients with brain diseases
The Austrian Federal Economic Chamber functions as the federal parent organization for the nine State Chambers and 110 trade associations for different industries within Austria's system of economy.
Show more...Investment focus
- Industry: Software, Music, mHealth
- Stage:Seed, Pre-Seed
- Geography: Austria
Investor stats
- Total investments: 3
- Lead/follow: no public data
Portfolio highlights
- Music Traveler — Music Traveler is a rapidly growing aggregator and marketplace, bringing a highly fragmented B2B and B2BC environment to the sharing economy. Music Traveler centralises practice/rehearsal/performing spaces, equipment, and instruction for the performing arts – its mission is to promote the creation, appreciation and interest in music byy reducing barriers, facilitating new interactions.
- The Apollinaire Group (TAG) — Intelligent supply chain management company.
- SCARLETRED — SCARLETRED is an international Digital Health Scaleup revolutionising the global skin care market by the AI powered SCARLETRED®VISION platform system. The problem we solved is subjective skin assessment and lacking standardization in Dermatology. Our medical device certified platform is fully mobile, runs via mobile App on smartphones and connectsto our web platform, which enables to generate smart imaging data and novel AI decision support applications in Dermatology and Telemedicine. The multi award winning technology is supplied international via SaaS to Biopharma and Cosmetics Industry, Hospitals and Medical Experts. Protected via worldwide patents it facilitates standardized skin documentation and remote tracking of skin changes and therapeutic effects via mobile App. Images can be uploaded in a cloud based platform and objectively analysed for visual skin changes over time, such as for allergic reactions, pigmentation changes, acne, psoriasis, disease or wound healing. SCARLETRED provides services on a broad range of dermatologic conditions ranging from B2B to B2B2C applications.
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Grant, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 124
- Round size: Grant $1.6M–$10M; Series C $10M–$127M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $319M in 2018
Portfolio highlights
- Lario Therapeutics — Lario Therapeutics is a biopharmaceutical firm that develops precision therapeutics for epilepsy and neurological disorders.
- Wysa — Use Wysa to vent or just talk through negative thoughts and emotions. Let it help you cope with pandemic anxiety and lockdowns. It is anonymous, safe and free.
- Ineffable Intelligence — Ineffable Intelligence develops machine learning systems that learn through interaction and experience. The company works on reinforcement learning approaches that allow models to improve by trial and error rather than relying on large human-generated datasets. Its core work centers on building a “superlearner,” a system designed to generateknowledge and skills by engaging with simulated or real environments.The organization develops algorithms and computational frameworks that support autonomous learning, experimentation, and decision-making processes. Its efforts involve designing AI models that can adapt, refine behavior, and solve complex problems through continuous feedback loops. The company’s research aims to expand how AI systems acquire knowledge and apply it across different domains.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 200
- Round size: Series A $19M–$176M; Series B $16M–$155M; Series C $19M–$113M
- Lead/follow: 52% lead, 48% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Inflazome — Situs gacor premium Megawin188 paling banyak di minati oleh semua kalangan karena pecah selayar tanpa henti dan memiliki tampilan yang sangat memanjakan mata.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
FCPG Affi
Show more...Investment focus
- Industry: Medical, Biotechnology, Pharmaceutical
- Geography: Austria
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- AFFiRiS — AFFiRiS AG, a Vienna, Austria-based developer of tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, hypertension and several other conditions.
GLS Ventures
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series B
- Geography: Austria
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Nabriva Therapeutics — MPOMM Adalah link resmi berlisensi agen mpo slot paling gacor hari ini dengan pilihan bermain di server slot anti rungkat terjamin kemenangan jackpot maxwin menang berapapun akan di bayar lunas
Synthesis Capital is an investment manager transforming our food system through food technology.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Organic Food
- Stage:Seed, Series A, Series C
- Geography: United States, Israel, Austria
Investor stats
- Total investments: 10
- Round size: Seed $7.1M–$9M; Series A $20M–$23M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Triplebar — Triplebar provides sustainability, biotechnology, and synthetic biology research.
- Savor — Savor makes delightfully rich foods without animals, farmland, fertilizers, hormones, or antibiotics.
- Culture Biosciences — Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditionalapproaches by robotic sample handling and cloud data monitoring and analysis.Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Grant, Pre-Seed, Seed
- Geography: United Kingdom, Spain, Ireland
Investor stats
- Total investments: 97
- Round size: Seed $220k–$1.4M; Grant $22k–$1.6M; Pre-Seed $44k–$1.4M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- IDOVEN — IDoven develops products to detect heart problems at an early stage to prevent heart diseases.
- Noah Labs — A breakthrough for heart failure: Noah Labs Ark is a Class IIa Medical Device Software with AI-driven detection of early cardiac decompensation through voice.
- Trak — Trak is a software tool for healthcare professional to provide AI-based tele-rehabilitation services like physiotherapy and others.
Investing in the ReGeneration
Show more...Investment focus
- Industry: Biotechnology, Agriculture, Farming
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 20
- Round size: Seed $3.4M–$8M; Pre-Seed $2M–$2.3M; Series A $6M–$20M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely still investing — raised $50M in 2021
Portfolio highlights
- Asterix Foods — Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel.
- Differential Bio — Differential Bio is integrating scale-down experiments with AI-based modeling to optimize how industry-relevant microbes grow ("biomass fermentation") and produce ("precision fermentation"). By optimizing bioprocesses and growth conditions, the company is not only increasing their clients' R&D efficiency but alsodramatically improving bioproduction outcomes such as yield, cost efficiency, and product quality.
- Ulysses Ecosystem Engineering — Ulysses rewild the ocean and remove gigatons of carbon, contributing to global efforts to combat climate change and restore marine ecosystems.
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, Ireland, Singapore
Investor stats
- Total investments: 461
- Round size: Series A $4.5M–$83M; Series B $7M–$107M; Series C $10M–$100M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $182M in 1998
Portfolio highlights
- Living Proof — Living Proof was created for the purpose of applying advanced technology to solve the toughest beauty challenges from a completely fresh perspective. They are a team of scientists from outside beauty, led by MIT Institute Professor Dr. Bob Langer, and beauty authorities with a shared vision: to invent efficient formulas based on entirely newmolecules and breakthrough technologies for results you can see from across the room.
- ReadyForZero — ReadyForZero creates online financial software that helps people tackle any debt and protect their credit - automatically. It's not a "debt negotiation" or "debt settlement" service. The company was co-founded by Rod Ebrahimi and Ignacio Thayer as part of Y Combinator in the Summer of 2010. ReadyForZero is aventure-backed technical product team based in San Francisco.
- Seamless Receipts — Extensive selection of high-quality domain names. Knowledgeable, friendly customer support.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life.
Show more...Investment focus
- Industry: Health Care, Biotechnology
- Stage:Seed
- Geography: Austria
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Panoptes Pharma — Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes is located in the city center of Vienna, Austria.The development of Panoptes´ clinical candidate PP-001 focuses on a new treatment for autoimmune uveitis, a disease whichis one of the major causes of blindness. As a second indication, adenoviral conjunctivitis will be pursued, a disease for which to date, no treatment is available. Due to its unique mode of action, PP-001 has therapeutic potential for additional inflammatory and viral indications.Panoptes has an experienced team of development experts with a proven track record of developing and commercializing innovative products. The team is developing a focused portfolio of high-performance small molecule products, with its lead clinical candidate PP-001 in preclinical development.
Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Private Equity
- Geography: France, United States, Germany
Investor stats
- Total investments: 180
- Round size: Series B $14M–$85M; Private Equity $110M–$247M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $466M in 2022
Portfolio highlights
- Senstronic — Senstronic designs and manufactures industrial sensing solutions focused on performance, reliability and technical expertise for demanding applications.
- Inventiva Pharma — Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.They have built a pipeline backed by a discovery engine with an extensive library ofproprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
- Rivermark Medical — Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function. Developed by urologists to reliably reduce BPH symptoms with minimal side effects.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 615
- Round size: Series A $10M–$140M; Series B $24M–$151M; Series C $15M–$131M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Avedro — Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the UnitedStates, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
- EDDA Technology — EDDA Technology offers computer assistance to the patient care management cycle and enables early detection and diagnosis of diseases.
Air Street Capital provides venture capital funding and strategic support focused on early-stage companies that develop products based on artificial intelligence. It invests primarily at pre-seed, seed, and Series A stages in firms working on AI-first technology, software infrastructure, machine-learning tools, and AI-enabled life scienceapplications. The firm pairs capital investment with advisory input on product, market, and technology strategy, and facilitates connections to its broader network of AI and technology stakeholders. Air Street Capital also shares industry insights through publications and community initiatives aimed at supporting AI and related tech ecosystems.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 48
- Round size: Seed $2.6M–$15M; Series A $10M–$53M; Series B $64M–$300M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- STARK — EUROPEAN DEFENCE SOVEREIGNTY
- Profluent Bio — Profluent Bio is an AI-first protein design company that designs novel, optimal proteins that bypass existing barriers in industry.
- Macrodata Labs — Macrodata Labs is a technology company that provides data infrastructure for the artificial intelligence and robotics industries.
We are peers amongst entrepreneurs helping the brave to build game-changing companies, just like we have done ourselves.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, France, Sweden
Investor stats
- Total investments: 96
- Round size: Seed $2.2M–$6M; Pre-Seed $1.3M–$2.3M; Series A $2.3M–$28M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- ALP Bio — Alp Bio’s platform integrates tonsil organoid technology with advanced protein AI to identify and mitigate immunogenic risks in therapeutic antibodies, ensuring safer patient outcomes.
- Flowlity — Flowlity revolutionizes planners' experience by streamlining tasks within planning tools and automating 95% of planning activities.
- Quillon — Quillon develops artificial intelligence software designed for technical accounting and financial reporting workflows. The platform enables users to research accounting standards, analyze regulatory filings, and interpret contractual documents with outputs linked to source references for traceability. It provides tools for drafting structuredaccounting memos, performing peer benchmarking across filings, and executing compliance checklists within a unified workspace. The system integrates data from frameworks such as US GAAP and IFRS, along with public filing databases, to support decision-making in areas like revenue recognition and financial disclosures. Quillon also includes collaboration and document editing features that allow teams to review, revise, and finalize reporting materials within the platform.
Venture Partners AG is a leading European Venture firm with locations in Switzerland and Boston.
Show more...Investment focus
- Industry: Internet, Software, Biotechnology
- Stage:Seed, Series B
- Geography: Austria, United States
Investor stats
- Total investments: 2
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Allcyte — At Exscientia, we combine the power of AI and human creativity to make safer and more sophisticated drugs available to all. Visit our website to find out more.
- apps4biz.com — At apps4biz.com™, ease-of-use and affordability are Their passion. They understand that a small business does not have the resources to learn, implement and fully utilize complex systems. apps4biz.com solutions enable you to quickly take advantage of your investment. And, you can easily tailor the apps4biz.com solution to accommodate your businessnow, and as your company grows.
Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 45
- Round size: Seed $2.4M–$15M; Pre-Seed $125k–$7.8M; Series A $12M–$37M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Calibre — Calibre uses causal AI in conjunction with clinical expertise to help people understand what is truly influencing their health and how to modify it.
- Modern Relay — Modern Relay provides context graph for enterprise AI.
- Theorema — Autonomous R&D agents for biotech, pharma, chemicals, and materials. Theorema analyzes data, recovers R&D costs, and accelerates discovery. #1 on BixBench.
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Australia, United States
Investor stats
- Total investments: 164
- Round size: Seed $1.6M–$10M; Pre-Seed $549k–$3.8M; Series A $9.7M–$47M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- EntryLevel — Learn in an affordable, peer-driven environment over 6 weeks with mentors from top companies across the world such as Atlassian, Wise and more.
- Sizable energy — Sizable Energy addresses the critical need for secure, affordable, and sustainable energy storage. Sizable Energy patented technology and straightforward design extends pumped hydro deployment to any offshore location with a depth of at least a few hundred meters. By leveraging a novel, modular, and easily deployable method, we utilize thegravitational potential of a solution 20% heavier than seawater, like saturated sea salt brine, within seawater.
- Koala Go — Your student's favorite online classroom. 24/7 live support. Co-browser. Gamified teaching environment. Worldwide invoicing. Interactive whiteboard.
EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Germany, Austria, Ireland
Investor stats
- Total investments: 11
- Round size: Series A $3.9M–$15M; Series B $20M–$70M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
- Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
venture capital
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: Hungary, South Korea, United States
Investor stats
- Total investments: 28
- Round size: Seed $424k–$31M; Series A $1.3M–$2.3M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Cytocast — Cytocast is leveraging the integration of bioinformatics databases and patient data within a computer model to create a groundbreaking cell simulation software. This software holds the potential to revolutionize patient treatment, significantly impact the drug development process, and enable the identification of optimal therapeutic options. Thecomprehensive cell model that forms the basis of the technology combines molecular knowledge of how healthy cells function to understand the effects of perturbations caused by diseases and predict how drugs can modify cellular health.
- Iskra — Iskra offers web3 gaming opportunities using blockchain and rewards its stakeholders based on their participation.
- On Vacation — On Vacation is a chat-based concierge service where customers may get help making reservations and getting personalized and optimal tours from travel specialists.
Biotechnology VC funding in Austria at a glance
Stats across 118 deals from 148 investors.
Access all 148 VC funds in Austria Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology VC Funds in Austria investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 148 VC funds investing in Austria Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!